Download or read book Analysis of the German Biotech Industry written by Dannie Anders Nelson and published by . This book was released on 2006 with total page 37 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Parameters of Regional Cooperative Behavior in the German Biotech Industry written by Timo Mitze and published by . This book was released on 2012 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Public R D Policy written by Andreas Fier and published by . This book was released on 2014 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: The German biotechnology industry missed the accession of this key technology in the 1980s. Policy makers make different efforts to overcome shortcomings and recent gaps. Public funding schemes have been implemented to establish a flourish biotech industry in Germany. We assume that R&D policy was driven blind by the idea to catch up with world's biotech leaders and analyse if Germany's R&D policy lost its origins. We do examine, if Germany sacrifice economic funding principles, in particular not discriminating different kinds of "risk" in the field of biotechnology. The study combines survey data of German biotech companies and public R&D funding data on the firm level. The results shed light on the factors which determine public R&D funding and firm's probability of being funded.
Download or read book THE ADOPTION AND ADAPTION OF OPEN INNOVATION EMPIRICAL EVIDENCE FROM THE BIOTECHNOLOGY INDUSTRY written by RAFAELA KUNZ and published by Archers & Elevators Publishing House. This book was released on with total page 266 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The Determinants of Firm Growth in High Technology Industries written by Julian Kahl and published by . This book was released on 2015 with total page 278 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Analysis of the Bio and Nano technological Market of Germany to Find Market Entry Strategies for Chosen IBM Research Developments written by Daniel Bartel and published by GRIN Verlag. This book was released on 2011-02 with total page 25 pages. Available in PDF, EPUB and Kindle. Book excerpt: Essay from the year 2011 in the subject Business economics - Business Management, Corporate Governance, grade: keine, University of Cooperative Education Stuttgart, course: Intercultural Management, language: English, abstract: In this seminar paper I want to discuss about IBM's efforts in the biotechnology and nanotechnology sector. As the lecture international management designated I will coin these efforts with strategies of market entry within Germany. I have chosen IBM, a US-based company, because it is highly involved in building future technologies. The Company is well known for its activities around the world and sees itself as a globally integrated enterprise. However, cultural attitudes of different countries still determine the success or failure of market entries. Germany is known as a technology-leading country. Also dealing with powerful NGO's the success of new market entry with modern technology might seems less predictable . In the first part of this paper I give a brief description about IBM, its research fields related to the topic and outline four research examples. Followed by an introduc-tion of Germany's cultural attitude to bio- and nanotechnology I provide some strategic suggestions on how IBM could manage the expansion of its efforts within the targeted country.
Download or read book The Birth of German Biotechnology Industry written by Claire Champenois and published by . This book was released on 2018 with total page 37 pages. Available in PDF, EPUB and Kindle. Book excerpt: The goal of this paper is to point out the role played by private equity investors (venture-capital companies and corporate investors) in the emergence of a new biotechnology industry in Germany in the second half of the 90's. This analysis takes into account the different business models and business fields to be found in the biotechnology industry. Based on theoretical arguments, a great relevance of VC-companies in financing young innovative biotechnology firms developing health care applications and technology platforms is expected, whereas corporate investors like pharmaceutical and chemical industries should play a more important role in financing supplier companies. Corporate investors are also expected to be significantly present in the equity financing of health care biotechnology companies. Empirical results from descriptive and multivariate analyses confirm all hypotheses but one: surprisingly, corporate investors invested only marginally in the equity funding of biotechnology firms developing new health care products or services.Published in Applied Economics, Vol. 38, No. 5, 2006 under the title of quot;What Kind of Biotechnology Start-Ups Do Venture Capital Companies and Corporate Investors Prefer for Equity Investments?quot.
Download or read book Overcoming the bottlenecks in financing young biotech companies written by Sascha Berger and published by GRIN Verlag. This book was released on 2008-05-28 with total page 80 pages. Available in PDF, EPUB and Kindle. Book excerpt: Diploma Thesis from the year 2007 in the subject Business economics - Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl für Entrepreneurial Finance), language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle.
Download or read book 13th Guide to German Biotech Companies 2011 written by and published by . This book was released on 2011 with total page 224 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Red biotechnology in Germany written by Michael Mallek and published by GRIN Verlag. This book was released on 2010 with total page 25 pages. Available in PDF, EPUB and Kindle. Book excerpt: Studienarbeit aus dem Jahr 2010 im Fachbereich BWL - Sonstiges, Note: 1,9, Stuttgart Institute of Management and Technology, Veranstaltung: International Management, Sprache: Deutsch, Abstract: The entrance of biotechnology into medicine, especially driven by new genetic techniques, has led to promising new markets. Biotech companies are spending extraordinary sums in R&D before new technologies generate a return on the investment. In Germany alone biotech companies have spent more than half of their total revenues on R&D in 2008 which accounts for more than a billion Euros. Therefore it stands to reason for biotech companies to exploit as many markets - and thus as many countries - as possible to maximize the return on the investment. In this academic paper Oxford Fertility Unit will serve as a representative example for red biotech companies. It is a Great Britain based fertility treatment and reproductive medicine company offering Assisted Reproductive Technology (ART) services. Entering the German market would call for a elaborate market entrance strategy as Oxford Fertility Unit would face challenging market uniquenesses derived from culture and politics for intstance. Hence, it serves as a great case study to exemplify such factors that arise when entering new markets outside the home country and how to deal with them. This paper will focus on the analysis of these factors as a requisite to draft a market entrance strategy.
Download or read book Finance Innovation and Geography written by Felix C. Müller and published by Routledge. This book was released on 2019-05-14 with total page 200 pages. Available in PDF, EPUB and Kindle. Book excerpt: The overarching aim of Finance, Innovation and Geography: Harnessing Knowledge Dynamics in German Biotechnology is to explore linkages between geographies of finance and relational geographies of innovation. This is achieved by questioning how investment activities affect the unfolding of innovations and in turn are affected by it. This book focuses on biotechnology innovation processes from the perspective of relational economic geography. It reconstructs the unfolding in time and space of eight innovations in German biotechnology. Each one is represented in a qualitative case study. The analysis focuses on the relational work of building, transforming, ending and replacing of collaborative relationships and organizational arrangements surrounding emergent innovations ・ including investment relations and relational work by investors. In this way, the contribution of investors to unfolding innovations is studied with sensitivity to context and situated interactions. The geography of these dynamics is conceptualized by drawing on the recent literature on relational proximity and distance as well as ideas of materiality and space. This book provides a unique perspective, and shows that innovation paths are strongly interwoven with local and temporary opportunities as well as crises, and that investment is embedded in these dynamics. This is essential reading for students and academics of both economics and innovation.
Download or read book BioRegio BioProfile and the Rise of the German Biotech Industry written by Dirk Dohse and published by . This book was released on 2008 with total page 32 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Overcoming the Bottlenecks in Financing Young Biotech Companies written by Sascha Berger and published by GRIN Verlag. This book was released on 2008-06 with total page 86 pages. Available in PDF, EPUB and Kindle. Book excerpt: Diploma Thesis from the year 2007 in the subject Business economics - Investment and Finance, grade: 1,3, Technical University of Munich (KfW Stiftungslehrstuhl f r Entrepreneurial Finance), 148 entries in the bibliography, language: English, abstract: In this book the question of how to overcome specific bottlenecks in financing young biotech companies was posed. The answer is manifold and includes the the usage of the multitude of financial options. Hence, first, the unique characteristics of the industry were described and specific financial bottlenecks were revealed. The eminence of a major bottleneck, typically in the seed-phase of a biotech venture, was taken as reason for further elaborations. I based these elaborations primarily upon an analysis of interviews. Several qualitative and predominantly personal interviews were conducted in the Munich biotech cluster, covering three decisive groups of respondents: biotech executives and founders, venture capital investors and external industry experts. The obtained extensive experiences were finally collected, clustered and compared. My key finding was that this bottleneck is mainly rooted in the fact that, when a young biotech firm leaves the academia, a big money provider (a Venture Capitalist or corporate partner) is often not yet willing to invest. A technological proof-of-concept is demanded by the latter, which is, however, not yet sufficiently provided by the former. Cluster structures might generally be helpful, but do not change this fundamental logic either. Based on this analysis, and taking into account the many other revealed points to improve, I came up with an exhaustive roadmap how to tackle the bottlenecks, covering all major endogenous and exogenous factors. This list of suggestions was supplemented with some basic thoughts on biotech finance strategies as also lastly a description of a comprehensive biotech finance cycle.
Download or read book Guide to German Biotech Companies written by BIO Deutschland and published by . This book was released on 2008 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book 24th Guide to German Biotech Companies written by Andreas Mietzsch and published by . This book was released on 2021 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Guide to German Biotech Companies written by BIO Deutschland and published by . This book was released on 2007 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book 22nd Guide to German Biotech Companies 2020 written by Andreas Mietzsch and published by . This book was released on 2020-10-26 with total page 256 pages. Available in PDF, EPUB and Kindle. Book excerpt:
